📊 ICUCW Key Takeaways
Is ICUCW a Good Investment? Thesis Analysis
Early-stage medical device company with exceptional gross margins (95.7%) and explosive revenue growth (814% YoY), but unsustainable cash burn (-$13.6M annually) against minimal revenue ($1.2M) creates critical 11-month funding runway. Severe operating losses (-986.6% margin) and dilution risk from inevitable capital raise outweigh early commercialization promise.
Why Buy ICUCW? Key Strengths
- Exceptional 95.7% gross margin indicates superior product economics and pricing power
- Extraordinary 814% YoY revenue growth demonstrates strong early market adoption and commercial traction
- Fortress balance sheet with $12M cash position and minimal debt (0.05x Debt/Equity), providing flexibility
ICUCW Investment Risks to Consider
- Critical cash runway of only ~11 months given -$13.6M annual operating cash burn rate against $12M cash balance
- Massive operating expense structure: -$12.2M operating loss on just $1.2M revenue indicates severe cost inefficiency unrelative to revenue scale
- Pre-profitability stage with no visible path to breakeven requires substantial dilutive capital raise, eroding shareholder value
Key Metrics to Watch
- Quarterly revenue growth rate sustainability and deceleration trajectory
- Monthly cash burn trend and updated runway calculation for urgency of funding
- Operating expense ratio to revenue and progress toward gross margin leverage into operating profitability
ICUCW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.63x current ratio provides a solid financial cushion.
ICUCW Profitability Ratios
ICUCW vs Healthcare Sector
How SeaStar Medical Holding Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ICUCW Overvalued or Undervalued?
Based on fundamental analysis, SeaStar Medical Holding Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ICUCW Balance Sheet & Liquidity
ICUCW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: SeaStar Medical Holding Corp's revenue has grown significantly by 814% over the 5-year period, indicating strong business expansion. The most recent EPS of $-30.26 indicates the company is currently unprofitable.
ICUCW Growth Metrics (YoY)
ICUCW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $68.0K | -$2.0M | N/A |
| Q2 2025 | N/A | -$2.0M | $-0.18 |
| Q1 2025 | N/A | -$3.8M | $-0.44 |
| Q3 2024 | N/A | -$2.4M | $-1.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ICUCW Capital Allocation
ICUCW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for SeaStar Medical Holding Corp (CIK: 0001831868)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ICUCW
What is the AI rating for ICUCW?
SeaStar Medical Holding Corp (ICUCW) has an AI rating of SELL with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ICUCW's key strengths?
Claude: Exceptional 95.7% gross margin indicates superior product economics and pricing power. Extraordinary 814% YoY revenue growth demonstrates strong early market adoption and commercial traction.
What are the risks of investing in ICUCW?
Claude: Critical cash runway of only ~11 months given -$13.6M annual operating cash burn rate against $12M cash balance. Massive operating expense structure: -$12.2M operating loss on just $1.2M revenue indicates severe cost inefficiency unrelative to revenue scale.
What is ICUCW's revenue and growth?
SeaStar Medical Holding Corp reported revenue of $1.2M.
Does ICUCW pay dividends?
SeaStar Medical Holding Corp does not currently pay dividends.
Where can I find ICUCW SEC filings?
Official SEC filings for SeaStar Medical Holding Corp (CIK: 0001831868) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ICUCW's EPS?
SeaStar Medical Holding Corp has a diluted EPS of $-0.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ICUCW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, SeaStar Medical Holding Corp has a SELL rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ICUCW stock overvalued or undervalued?
Valuation metrics for ICUCW: ROE of -116.6% (sector avg: 15%), net margin of -984.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ICUCW stock in 2026?
Our dual AI analysis gives SeaStar Medical Holding Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ICUCW's free cash flow?
SeaStar Medical Holding Corp's operating cash flow is $-13.6M, with capital expenditures of N/A. FCF margin is -1,102.0%.
How does ICUCW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -984.6% (avg: 12%), ROE -116.6% (avg: 15%), current ratio 3.63 (avg: 2).